PAREXEL: The right partner for your early phase studies

Well-designed Phase I/IIa trials provide the robust data you need to avoid unnecessary developmental delays, reduce your risk of costly later-stage trial failures, and support earlier, better-informed “go/no-go” decisions.  PAREXEL has the global capabilities to keep your early-stage products moving forward quickly and efficiently – from exploratory INDs to First in Human testing and Proof of Concept studies.

We offer fully integrated Phase I through Phase IIa development programs across a wide spectrum of therapeutic areas, utilizing our strategic network of early phase clinical  units in the US, UK, Germany and South Africa.  This network provides ready access to the resources you need for successful early phase trials, including more than 400 beds, highly trained physicians, experienced research technicians, advanced clinical technology, and access to extensive databases of healthy volunteers and pre-qualified patient populations.  

PAREXEL also provides dedicated support for Proof of Concept studies, which are designed to demonstrate early signals of product’s efficacy in the targeted patient population.  We integrate our expertise in drug development, regulatory strategies, and clinical pharmacology so you can make better and faster decisions about which products have the best potential for success – reducing your chances of costly late-stage clinical development failures.

As a result of the growing importance of the Asia-Pacific market, ethnobridging studies are also a vital part of many early phase trials.  PAREXEL is a world leader in performing ethnobridging trials.  We have successfully conducted over 80 ethnobridging studies enrolling more than 1,000 patients, and PAREXEL scientists have worked closely with Asian regulators to design studies that will deliver acceptable data for their agencies.